Estradiol Prevents Fat Accumulation and Overcomes Leptin Resistance in Female High-Fat Diet Mice

• Published in: Endocrinology (Philadelphia) Vol. 155; no. 11; pp. 4447 - 4460
• Main Authors: Litwak, Sara A, Wilson, Jenny L, Chen, Weiyi, Garcia-Rudaz, Cecilia, Khaksari, Mohammad, Cowley, Michael A, Enriori, Pablo J
• Format: Journal Article
• Language: English
• Published: United States Endocrine Society 01.11.2014
• Subjects: Animals; Diet, High-Fat; Drug Resistance - drug effects; Estradiol - pharmacology; Female; Leptin - pharmacology; Lipid Metabolism - drug effects; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity - etiology; Obesity - metabolism; Obesity - prevention & control; Ovariectomy; Sex Factors
• ISSN: 0013-7227; 1945-7170
• DOI: 10.1210/en.2014-1342

In premenopausal and menopausal women in particular, suboptimal estrogens have been linked to the development of the metabolic syndrome as major contributors to fat accumulation. At the same time, estrogens have been described to have a role in regulating body metabolic status. We evaluated how endogenous or administered estrogens impact on the changes associated with high-fat diet (HFD) consumption in 2 different paradigms; ovarian-intact and in ovariectomized mice. When estradiol (E2) was cyclically administered to ovarian-intact HFD-fed mice for 12 weeks, animals gained significantly less weight than ovarian-intact vehicle controls (P < .01). This difference was mainly due to a reduced caloric intake but not to an increase in energy expenditure or locomotor activity. This E2 treatment regime to mice exposed to HFD was overall able to avoid the increase of visceral fat content to levels of those found in mice fed a regular chow diet. In the ovariectomized model, the main body weight and fat content reducing action of E2 was not only through decreasing food intake but also by increasing the whole-body energy expenditure, locomotor activity, and by inducing fat oxidation. Importantly, these animals became responsive to the anorexigenic effects of leptin in contrast to the vehicle-treated and the pair-fed control groups (P < .01). Further, in vitro hypothalamic secretion experiments revealed that treatment of obese mice with E2 is able to modulate the secretion of appetite-regulating neuropeptides; namely, E2 increased the secretion of the anorectic neuropeptide α-melanocyte-stimulating hormone and decreased the secretion of the orexigenic neuropetides neuropeptide Y and Agouti-related peptide. In conclusion, differences in response to E2 treatment of HFD-fed animals depend on their endogenous estrogenic status. Overall, E2 administration overcomes arcuate leptin resistance and partially prevents fat accumulation on these mice.